Back to top
more

Accelerate Diagnostics (AXDX)

(Real Time Quote from BATS)

$0.94 USD

0.94
2,841

-0.01 (-1.05%)

Updated Apr 24, 2024 03:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of -10.20% and 0.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of -2.70% and 20.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Codex DNA (DNAY) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Codex DNA (DNAY) delivered earnings and revenue surprises of 12.50% and 25.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Apollo Endosurgery, Inc. (APEN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of -33.33% and 8.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Silk Road Medical (SILK) Stock Jumps 6.7%: Will It Continue to Soar?

by Zacks Equity Research

Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Masimo (MASI) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 13.45% and 4.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Alphatec (ATEC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alphatec (ATEC) delivered earnings and revenue surprises of -2.86% and 7.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SeaSpine Holdings (SPNE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

SeaSpine (SPNE) delivered earnings and revenue surprises of -8.57% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 21.88% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Venus Concept (VERO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Venus Concept (VERO) delivered earnings and revenue surprises of -30% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Avinger (AVGR) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Avinger (AVGR) delivered earnings and revenue surprises of -92.56% and 0.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Avanos Medical (AVNS) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Avanos Medical (AVNS) delivered earnings and revenue surprises of 8.33% and 0.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 23.33% and 3.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sensus Healthcare, Inc. (SRTS) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 128.57% and 18.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 57.14% and -11.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Accelerate Diagnostics (AXDX) Q3 Earnings Expected to Decline

by Zacks Equity Research

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -2.86% and -12.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for June 2nd

by Zacks Equity Research

BEP, AXDX, FURY, KBAL, and LUNA have been added to the Zacks Rank #5 (Strong Sell) List on June 2, 2021

New Strong Sell Stocks for May 20th

by Zacks Equity Research

AXDX, CRIS, FSTR, GO, and PRLB have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2021

New Strong Sell Stocks for May 14th

by Zacks Equity Research

AXDX, CDR, FPAY, GCI, and IRTC have been added to the Zacks Rank #5 (Strong Sell) List on May 14, 2021

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -24.24% and -29.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Accelerate Diagnostics (AXDX) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Accelerate Diagnostics (AXDX) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.